 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || 5-methoxy-dimethyltryptamine dry-powder intranasal (BPL-003) / Beckley Psytech
P1 data, PK/PD data, Journal: Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants. (Pubmed Central) - Apr 15, 2024
P1
The short duration of action and induction of mystical experiences suggest clinical potential, warranting further trials. NCT05347849.
- ||| 5-methoxy-dimethyltryptamine dry-powder intranasal (BPL-003) / Beckley Psytech
Phase classification, Enrollment change, Trial completion date, Trial primary completion date: An Open-Label, Single Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression (clinicaltrials.gov) - Feb 15, 2024
P2, N=52, Recruiting, Sponsor: Beckley Psytech Limited
NCT05347849. Phase classification: P2a --> P2 | N=12 --> 52 | Trial completion date: Oct 2023 --> Nov 2024 | Trial primary completion date: Oct 2023 --> Nov 2024
- || 5-methoxy-dimethyltryptamine dry-powder intranasal (BPL-003) / Beckley Psytech
Trial completion date, Trial primary completion date: Single Ascending Dose Study With BPL-003 in Healthy Subjects (clinicaltrials.gov) - Sep 18, 2023
P1, N=65, Recruiting, Sponsor: Beckley Psytech Limited
Phase classification: P2a --> P2 | N=12 --> 52 | Trial completion date: Oct 2023 --> Nov 2024 | Trial primary completion date: Oct 2023 --> Nov 2024 Trial completion date: Aug 2023 --> Dec 2023 | Trial primary completion date: Aug 2023 --> Dec 2023
- |||| 5-methoxy-dimethyltryptamine dry-powder intranasal (BPL-003) / Beckley Psytech
Enrollment open: BPL-003 Efficacy and Safety in Treatment Resistant Depression (clinicaltrials.gov) - Sep 18, 2023
P2, N=225, Recruiting, Sponsor: Beckley Psytech Limited
Trial completion date: Aug 2023 --> Dec 2023 | Trial primary completion date: Aug 2023 --> Dec 2023 Not yet recruiting --> Recruiting
- ||||| 5-methoxy-dimethyltryptamine dry-powder intranasal (BPL-003) / Beckley Psytech
New P2 trial: BPL-003 Efficacy and Safety in Treatment Resistant Depression (clinicaltrials.gov) - May 23, 2023
P2, N=225, Not yet recruiting, Sponsor: Beckley Psytech Limited
- 5-methoxy-dimethyltryptamine dry-powder intranasal (BPL-003) / Beckley Psytech
Intranasal 5-MeO-DMT: Safety, Pk and Effect on Altered States of Consciousness in Healthy Volunteers (Sapphire AB) - Apr 29, 2023 - Abstract #SOBP2023SOBP_194;
Short duration of action and induction of mystical experiences suggest potential clinical advantages. Further clinical trials in patient populations are warranted.
- || 5-methoxy-dimethyltryptamine dry-powder intranasal (BPL-003) / Beckley Psytech
Trial completion date, Trial primary completion date: Single Ascending Dose Study With BPL-003 in Healthy Subjects (clinicaltrials.gov) - Mar 30, 2023
P1, N=65, Recruiting, Sponsor: Beckley Psytech Limited
Further clinical trials in patient populations are warranted. Trial completion date: Feb 2023 --> Aug 2023 | Trial primary completion date: Feb 2023 --> Aug 2023
- || 5-methoxy-dimethyltryptamine dry-powder intranasal (BPL-003) / Beckley Psytech
Enrollment open, Trial initiation date: An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder (clinicaltrials.gov) - Mar 30, 2023
P2a, N=12, Recruiting, Sponsor: Beckley Psytech Limited
Trial completion date: Feb 2023 --> Aug 2023 | Trial primary completion date: Feb 2023 --> Aug 2023 Not yet recruiting --> Recruiting | Initiation date: Jan 2023 --> Apr 2023
- || 5-methoxy-dimethyltryptamine dry-powder intranasal (BPL-003) / Beckley Psytech
Enrollment open: An Open-Label, Single Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression (clinicaltrials.gov) - Feb 14, 2023
P2a, N=12, Recruiting, Sponsor: Beckley Psytech Limited
Not yet recruiting --> Recruiting | Initiation date: Jan 2023 --> Apr 2023 Not yet recruiting --> Recruiting
- || 5-methoxy-dimethyltryptamine dry-powder intranasal (BPL-003) / Beckley Psytech
New P2a trial: An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder (clinicaltrials.gov) - Jan 9, 2023
P2a, N=12, Not yet recruiting, Sponsor: Beckley Psytech Limited
- || 5-methoxy-dimethyltryptamine dry-powder intranasal (BPL-003) / Beckley Psytech
New P2a trial: An Open-Label, Single Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression (clinicaltrials.gov) - Dec 21, 2022
P2a, N=12, Not yet recruiting, Sponsor: Beckley Psytech Limited
- || 5-methoxy-dimethyltryptamine dry-powder intranasal (BPL-003) / Beckley Psytech
Trial completion date, Trial primary completion date: Single Ascending Dose Study With BPL-003 in Healthy Subjects (clinicaltrials.gov) - Oct 12, 2022
P1, N=65, Recruiting, Sponsor: Beckley Psytech Limited
Not yet recruiting --> Recruiting Trial completion date: Apr 2022 --> Feb 2023 | Trial primary completion date: Apr 2022 --> Feb 2023
- ||| 5-methoxy-dimethyltryptamine dry-powder intranasal (BPL-003) / Beckley Psytech
New P1 trial: Single Ascending Dose Study With BPL-003 in Healthy Subjects (clinicaltrials.gov) - Apr 25, 2022
P1, N=56, Recruiting, Sponsor: Beckley Psytech Limited